Villagrana-Zesati JR, Guerra-Infante FM, Sosa-González IE

Language: Spanish
References: 20
Page: 231-238
PDF size: 401.05 Kb.

ABSTRACT

Background: In the United States 19 million people acquire a sexually transmitted disease every year. Sexually transmitted diseases impact in gynecological terms because they may cause sterility, infertility and ectopic pregnancy.
Objective: To compare the effectiveness of two combinations of three oral antimicrobial drugs in the treatment of mixed cervicalvaginal infections, included those caused by Mycoplasma and Chlamydia trachomatis.
Material and method: A clinical, random, comparative, double-blind study included 50 patients assisting to infectology consult with diagnosis of mixed cervical-vaginal infection. Patients were divided into two groups: Group A (n = 25): fluconazole 37.5 mg, tinidazole 500 mg and azithromycin 250 mg; group B (n = 25): fluconazole 37.5 mg, tinidazole 500 mg and clindamycin 312.5 mg. Patients of both groups received two tablets twice p.o. for one day. Cultures were performed to corroborate the diagnosis and then to demonstrate effectiveness of the schemes studied. For the analysis of the data we used measures of central tendency, dispersion and inferential statistics for comparison of proportions by c² and Fisher’s exact tests with a significance level of p ‹ 0.05.
Results: All patient got clinical cure; however, regarding the microbiologic eradication a positive case was identified in group A, requiring rescue treatment. The compliance in both groups was of 100%. In both groups, statistical analysis did not show significant differences. Three patients in group A had mild adverse effects. Patients mean age was 33.4 ± 5.3 years.
Conclusions: Both treatments showed similar effectiveness against mixed cervical-vaginal infections. Microbiological efficacy was of 96% and 100% in group A and B, respectively, besides, scheme of group B was better tolerated.

REFERENCES

1. Center for Diseases Control and Prevention (CDC). Trends in Reportable Sexually Transmitted Diseases in the United States, December 2011.

2. McMillan HM, O’Carroll H, Lambert JS, Grundy KB, et al. Screening for Chlamydia trachomatis in asymptomatic women attending outpatient clinics in a large maternity hospital in Dublin, Ireland. Chlamydia Screening 2006;82:503-505.

3. Bakken IJ. Chlamydia trachomatis and ectopic pregnancy: recent epidemiological findings. Curr Opin Infect Dis 2008;21:77-82.

4. McMahon Group. Infectious Diseases Special Edition: Overview of Antifungal Agent, 2007:10-43.

5. Vazquez JA, Sobel JD. Candidiasis. Essentials of Clinical Mycology. 2011;Part 3:167-206.

6. Okun N, Gronau KA, Hannah ME. Antibiotics for bacterial vaginosis or Trichomonas vaginalis in pregnancy; a systematic review. Obstet Gynecol 2005;105:857-868.

7. Villagrana-Zesati R, Reyna-Figueroa J, Ortiz-Ibarra J. Shortterm therapy for mixed vaginal infections. Int J Gynecol Obstet 2006;92:149-150.

8. Centers for Disease Control and Prevention. Sexually Transmitted Diseases Treatment Guidelines, Diseases Characterized by Vaginal Discharge. Treatment Guidelines, 2010. MMWR 2010.

9. Lau CY, Qureshi AK. Azithromycin versus doxycycline for genital chlamydial infections: a meta-analysis of randomized clinical trials. Sex Transmit Dis 2002;29:497-502.

10. Sobel J, Peipert JF, McGregor JA, Livengoof C, et al. Efficacy of clindamycin vaginal ovule (3-day treatment) vs. clindamycin vaginal cream (7-day treatment) in bacterial vaginosis. Infect Dis Obstet Gynecol 2001;9:9-15.

11. Ivankovich MB, Leichliter JS, Douglas JM Jr. Measurement of sexual health in the U.S.: an inventory of nationally representative surveys and surveillance systems. Public Health Reports 2013;Supp 1:1-72.

12. Figueroa-Damián R, Narcio-Reyes L. Frecuencia de infecciones de transmisión sexual. Ginecol Obstet Mex 1994;62:93-97.

13. Rivera-Rivera L, Quiterio-Trenado M, Cruz-Valdez A, Conde-González C. Prevalencia de vaginitis y vaginosis bacteriana: asociación con manifestaciones clínicas, de laboratorio y tratamiento. Ginecol Obstet Mex 1996;64:26-35.

14. Villagrana-Zesati JR. Etiología de las infecciones de transmisión sexual en la adolescente. Enfermedades Infecciosas y Microbiología 2001;21:69.

15. Baltazar-Reyes MC, Rivera L, Cruz A, Hernández C. Prevalencia de infecciones de transmisión sexual y factores de riesgo concomitantes en sexo-servidoras de Cuautla, Morelos, México. Ginecol Obstet Mex 2005;73:36-47.

16. Khan J, Farzand R. Prevalence of Mycoplasma hominis and Ureaplasma urealyticum among women with unexplained infertility, with and without vaginitis and cervicitis. Afr J Microbiol Res 2011;5:861-864.

17. Center for Disease Control and Prevention, Sexually Transmitted Diseases. Chlamydia positivity by age group in women attending family planning clinics, 2009.

18. Brunton L, Lazo J, Parker K. Clindamicina. En: Las bases farmacológicas de la terapéutica de Goodman y Gilman. 11ª ed. Ciudad de México: McGraw-Hill, 2012;1188.

19. Hillier S, Holmes KK. Bacterial vaginosis in sexually transmitted diseases. 4th ed. Nueva York: McGraw-Hill, 2003;563- 572.

20. Brunton L, Lazo J, Parker K. Macrólidos (eritromicina, claritromicina y azitromocina). En: las bases farmacológicas de la terapéutica de Goodman y Gilman. 11ª ed. Ciudad de México: McGraw-Hill, 2012;1182-1186.